Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
AbbVie Inc ABBV
News
Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
The big winners of the tech wreck are biopharma stocks
AbbVie 3Q Revenue Rises on Strength in Immunology, Neuroscience
AbbVie Reports Third-Quarter 2026 Financial Results
The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18
Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma
Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence
AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
/C O R R E C T I O N - AbbVie/
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets
AbbVie On Pace for Record High Close — Data Talk
Abbvie's Crohn's Disease Drug Skyrizi Shows More Positive Results
AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
United States